UnitedHealth to cover Guardant Health’s Shield blood test for early colorectal cancer screening for adults 45 and older

UnitedHealth Group is adding coverage for Guardant Health’s Shield blood test for early colorectal cancer screening, according to a market report published Tuesday by Yahoo Finance.

The report says the coverage starts for eligible adults aged 45 and older, positioning the policy change as a first for a major commercial insurer in the U.S. With colorectal cancer, screening is often recommended starting at age 45 in the U.S., and a blood-based test could broaden access for people who do not undergo stool-based or colonoscopy screening at the same rate.

Guardant Health’s Shield test is designed to look for indicates associated with colorectal cancer using a blood sample. Under UnitedHealth’s coverage expansion, eligible members can access the test through their plan, the report says, though it does not provide details on the specific plan types included, member cost-sharing, or the criteria used by clinicians to determine eligibility.

The report frames the coverage decision as a notable channel shift for Shield, moving it from clinical availability into routine insurance reimbursement for a large swath of the commercial market.

A second market write-up also highlighted the coverage change, echoing that Shield’s blood test is now covered for eligible UnitedHealth Group members. That item did not, however, add specific contract terms or operational details about when reimbursement applies or how claims are processed.

Sector context matters because colorectal cancer screening is a high-stakes, long-running priority for payers and providers, linking screening choices to downstream utilization such as diagnostic follow-up procedures. Broad insurer coverage can increase patient uptake, which can affect how quickly screening targets are met across populations.

Still, UnitedHealth and Guardant have not disclosed in the cited report what percentage of members are covered, whether the change applies uniformly across all UnitedHealth commercial products, or how the reimbursement decision interfaces with physician ordering protocols and laboratory billing rules. The reporting also does not specify whether coverage is limited to certain risk profiles, test frequency intervals, or geographic regions.

What to watch next is how quickly claims and test volumes respond after coverage begins, and whether other large insurers follow with similar reimbursement policies for blood-based colorectal screening. Investors and clinicians will also look for further guidance on ordering, eligibility, and follow-up pathways after a positive or inconclusive result.